Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

141. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) 29543566 2018 04 26 1527-7755 36 13 2018 May 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2 (...) -Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). 1308-1316 10.1200/JCO.2017.75.9175 Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standard anthracycline-taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer. Here, we report the long-term outcomes. Methods Patients with HER2-positive tumors (n = 615) received

2018 EvidenceUpdates

142. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial 29697452 2018 04 26 1528-1140 2018 Apr 24 Annals of surgery Ann. Surg. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. 10.1097/SLA.0000000000002771 Conflicting evidence exists regarding the value of surgical resection of the primary in stage IV breast cancer patients (...) . The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing primary surgery followed by systemic therapy to primary systemic therapy in de novo stage IV breast cancer. Between 2011 and 2015, 90 previously untreated stage IV breast cancer patients were randomly assigned to surgical resection of the primary tumor followed by systemic therapy (Arm A) or primary systemic therapy (Arm B) in Austria. Overall survival (OS) was defined as the primary study endpoint. The trial

2018 EvidenceUpdates

143. Pectoral I Block Does Not Improve Postoperative Analgesia After Breast Cancer Surgery: A Randomized, Double-Blind, Dual-Centered Controlled Trial

Pectoral I Block Does Not Improve Postoperative Analgesia After Breast Cancer Surgery: A Randomized, Double-Blind, Dual-Centered Controlled Trial 29672368 2018 04 19 1532-8651 2018 Apr 18 Regional anesthesia and pain medicine Reg Anesth Pain Med Pectoral I Block Does Not Improve Postoperative Analgesia After Breast Cancer Surgery: A Randomized, Double-Blind, Dual-Centered Controlled Trial. 10.1097/AAP.0000000000000779 General anesthesia for breast surgery may be supplemented by using a regional (...) anesthetic technique. We evaluated the efficacy of the first pectoral nerve block (Pecs I) in treating postoperative pain after breast cancer surgery. A randomized, double-blind, dual-centered, placebo-controlled trial was performed. One hundred twenty-eight patients scheduled for unilateral breast cancer surgery were recruited. A multimodal analgesic regimen and surgeon-administered local anesthetic infiltration were used for all patients. Ultrasound-guided Pecs I was performed using bupivacaine

2018 EvidenceUpdates

144. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial 29501363 2018 04 03 1474-5488 19 4 2018 Apr The Lancet. Oncology Lancet Oncol. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. 497-509 S1470-2045(18)30111-6 10.1016 (...) /S1470-2045(18)30111-6 Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or carboplatin

2018 EvidenceUpdates

145. Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy (PubMed)

Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy 30370355 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy. 552-558 10.1016/j.adro.2018.05.007 This study aimed to explore the associations between dose (...) -volume parameters of localized breast irradiation, longitudinal interleukin-6 soluble receptor (sIL-6R), and leukocyte counts as markers of an immune-mediated response and fatigue as a centrally-driven behavior. This prospective cohort study recruited 100 women who were diagnosed with stage 0-IIIa breast cancer, prescribed 40 Gy in 15 fractions over 3 weeks adjuvant radiation therapy, and had no prior or concurrent chemotherapy. Dose-volume parameters were derived from treatment plans and related

Full Text available with Trip Pro

2018 Advances in radiation oncology

146. Machine learning for detection of lymphedema among breast cancer survivors (PubMed)

Machine learning for detection of lymphedema among breast cancer survivors 29963562 2018 11 14 2306-9740 4 2018 mHealth Mhealth Machine learning for detection of lymphedema among breast cancer survivors. 17 10.21037/mhealth.2018.04.02 In the digital era when mHealth has emerged as an important venue for health care, the application of computer science, such as machine learning, has proven to be a powerful tool for health care in detecting or predicting various medical conditions by providing (...) of lymphedema and long term clinical decision support for breast cancer survivors who face lifelong risk of lymphedema. Lymphedema, which is associated with more than 20 distressing symptoms, is one of the most distressing and dreaded late adverse effects from breast cancer treatment. Currently there is no cure for lymphedema, but early detection can help patients to receive timely intervention to effectively manage lymphedema. Because lymphedema can occur immediately after cancer surgery or as late as 20

Full Text available with Trip Pro

2018 mHealth

147. The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”? (PubMed)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”? 29845111 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer The PROMISe to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"? 12 10.1038/s41523-018-0064-8 Cardoso Fatima F Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. Curigliano Giuseppe G 2Department of Hematology and Oncology, European (...) Institute of Oncology, University of Milano, Via Ripamonti 435, 20141 Milano, Italy. 0000 0004 1757 2822 grid.4708.b eng Editorial 2018 05 22 United States NPJ Breast Cancer 101674891 2374-4677 F.C. is one of the principal investigators of the MINDACT trial. The authors declare no competing interests. 2018 02 08 2018 02 28 2018 04 17 2018 5 31 6 0 2018 5 31 6 0 2018 5 31 6 1 epublish 29845111 10.1038/s41523-018-0064-8 64 PMC5964184 Nat Clin Pract Oncol. 2006 Oct;3(10):540-51 17019432 N Engl J Med. 2016

Full Text available with Trip Pro

2018 NPJ breast cancer

148. Prognostic gene expression assays in breast cancer: are two better than one? (PubMed)

Prognostic gene expression assays in breast cancer: are two better than one? 29845110 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Prognostic gene expression assays in breast cancer: are two better than one? 11 10.1038/s41523-018-0063-9 Sparano Joseph A JA 0000-0002-9031-2010 Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY USA. 0000000121791997 grid.251993.5 eng P30 CA013330 CA NCI NIH HHS United States U10 CA180820 CA NCI NIH HHS United States UG1 (...) CA189859 CA NCI NIH HHS United States Editorial 2018 05 22 United States NPJ Breast Cancer 101674891 2374-4677 J.A.S. holds equity interest in MetaStat, Inc. 2017 11 11 2018 03 31 2018 04 06 2018 5 31 6 0 2018 5 31 6 0 2018 5 31 6 1 epublish 29845110 10.1038/s41523-018-0063-9 63 PMC5964115 J Natl Cancer Inst. 2016 Apr 29;108(9):null 27130929 NPJ Breast Cancer. 2017 Nov 8;3:42 29138761 NPJ Breast Cancer. 2016 Jun 08;2:16017 28721379 Breast Cancer Res. 2008;10(4):R65 18662380 J Clin Oncol. 2010 Apr 1;28

Full Text available with Trip Pro

2018 NPJ breast cancer

149. Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer (PubMed)

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer 29942922 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. 574-588 10.1210/js.2018-00052 Cancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important (...) component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostate cancer. Taxel Pamela P UConn Health Center, Farmington, Connecticut. Faircloth Erika E UConn Health Center, Farmington, Connecticut. Idrees Sana S Saint Vincent's Hospital, Bridgeport, Connecticut. Van Poznak Catherine C University of Michigan Health Center, Ann Arbor, Michigan. eng Journal Article Review 2018 05 21 United States J Endocr Soc 101697997 2472

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

150. Neoadjuvant treatment: the future of patients with breast cancer (PubMed)

Neoadjuvant treatment: the future of patients with breast cancer 29862051 2018 11 14 2059-7029 3 4 2018 ESMO open ESMO Open Neoadjuvant treatment: the future of patients with breast cancer. e000371 10.1136/esmoopen-2018-000371 Reyal F F Residual Tumor and Response to Treatment Laboratory, RT2Lab, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France. Breast and Gynecologic Cancer and Reconstructive Surgery Team, Institut Curie, Paris, France. Hamy A S (...) AS Breast and Gynecologic Cancer and Reconstructive Surgery Team, Institut Curie, Paris, France. Piccart Martine J MJ Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium. eng Editorial 2018 05 17 England ESMO Open 101690685 2059-7029 breast cancer Competing interests: None declared. 2018 04 05 2018 04 06 2018 6 5 6 0 2018 6 5 6 0 2018 6 5 6 1 epublish 29862051 10.1136/esmoopen-2018-000371 esmoopen-2018-000371 PMC5976132 J Clin Oncol. 2005 Apr 10;23(11):2477-92 15767642 J Clin Oncol

Full Text available with Trip Pro

2018 ESMO open

151. Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval (PubMed)

Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval 29764801 2018 11 30 2369-1999 4 1 2018 May 15 JMIR cancer JMIR Cancer Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval. e10 10.2196/cancer.9050 Patient education materials given to breast cancer survivors may not be a good fit for their information needs (...) . Needs may change over time, be forgotten, or be misreported, for a variety of reasons. An automated content analysis of survivors' postings to online health forums can identify expressed information needs over a span of time and be repeated regularly at low cost. Identifying these unmet needs can guide improvements to existing education materials and the creation of new resources. The primary goals of this project are to assess the unmet information needs of breast cancer survivors from their own

Full Text available with Trip Pro

2018 JMIR cancer

152. Acceptability of a Mobile Phone App for Measuring Time Use in Breast Cancer Survivors (Life in a Day): Mixed-Methods Study (PubMed)

Acceptability of a Mobile Phone App for Measuring Time Use in Breast Cancer Survivors (Life in a Day): Mixed-Methods Study 29759953 2018 11 14 2369-1999 4 1 2018 May 14 JMIR cancer JMIR Cancer Acceptability of a Mobile Phone App for Measuring Time Use in Breast Cancer Survivors (Life in a Day): Mixed-Methods Study. e9 10.2196/cancer.8951 Advancements in mobile technology allow innovative data collection techniques such as measuring time use (ie, how individuals structure their time (...) ) for the purpose of improving health behavior change interventions. The aim of this study was to examine the acceptability of a 5-day trial of the Life in a Day mobile phone app measuring time use in breast cancer survivors to advance technology-based measurement of time use. Acceptability data were collected from participants (N=40; 100% response rate) using a self-administered survey after 5 days of Life in a Day use. Overall, participants had a mean age of 55 years (SD 8) and completed 16 years of school

Full Text available with Trip Pro

2018 JMIR cancer

153. Outcome of Patients With Breast Cancer Treated in a Private Health Care Institution in Brazil (PubMed)

Outcome of Patients With Breast Cancer Treated in a Private Health Care Institution in Brazil 30241277 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Outcome of Patients With Breast Cancer Treated in a Private Health Care Institution in Brazil. 1-10 10.1200/JGO.17.00143 Middle-income countries like Brazil often have a dichotomous health care system in which patients may be treated in either public or private institutions that differ substantially in terms of level (...) of access to diagnostic and therapeutic procedures. This was a prospective, observational study to assess real-world data in 1,230 female patients with breast cancer who were treated in a private health care institution between 2012 and 2016 in Brazil. Breast cancer in these patients mostly was diagnosed at early (79.0% stages I or II) or locally advanced (16.1% stage III) stages. The primary tumor was resected in 89.0% of cases, most often through breast-conserving surgery (55.1%). Patients

Full Text available with Trip Pro

2018 Journal of global oncology

154. Skin recurrence in the radiation treatment of breast cancer (PubMed)

Skin recurrence in the radiation treatment of breast cancer 30202813 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Skin recurrence in the radiation treatment of breast cancer. 458-462 10.1016/j.adro.2018.04.014 Katz Leah M LM Department of Radiation Oncology, New York University Langone Health & Laura and Isaac Perlmutter Cancer Center, New York, New York. Perez Carmen A CA Department of Radiation Oncology, New York University Langone Health & Laura (...) and Isaac Perlmutter Cancer Center, New York, New York. Gerber Naamit K NK Department of Radiation Oncology, New York University Langone Health & Laura and Isaac Perlmutter Cancer Center, New York, New York. Purswani Juhi J Department of Radiation Oncology, New York University Langone Health & Laura and Isaac Perlmutter Cancer Center, New York, New York. McCarthy Allison A Department of Radiation Oncology, New York University Langone Health & Laura and Isaac Perlmutter Cancer Center, New York, New York

Full Text available with Trip Pro

2018 Advances in radiation oncology

155. Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications (PubMed)

Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications 29734696 2018 11 14 2227-9059 6 2 2018 May 04 Biomedicines Biomedicines Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications. E50 10.3390/biomedicines6020050 Cancer arises from subpopulations of transformed cells with high tumor initiation and repopulation ability, known as cancer stem cells (CSCs), which share many similarities with their normal (...) counterparts. In the mammary gland, several studies have shown common molecular regulators between adult mammary stem cells (MaSCs) and breast cancer stem cells (bCSCs). Cell plasticity and self-renewal are essential abilities for MaSCs to maintain tissue homeostasis and regenerate the gland after pregnancy. Intriguingly, these properties are similarly executed in breast cancer stem cells to drive tumor initiation, tumor heterogeneity and recurrence after chemotherapy. In addition, both stem cell

Full Text available with Trip Pro

2018 Biomedicines

156. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (PubMed)

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer 29761158 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. 10 10.1038/s41523-018-0060-z Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor (...) targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients with metastatic breast cancer. This was a non-randomized phase II study enrolling patients with refractory, metastatic triple-negative breast cancer. The primary endpoint was objective response by RECIST 1.1. The study was designed to enroll patients whose archival tumor tissue was pSTAT3-positive ( T -score >5) by central immunohistochemistry. pSTAT3 staining was available from 171 of 217 consented patients

Full Text available with Trip Pro

2018 NPJ breast cancer

157. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies (PubMed)

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies 29765774 2018 11 14 2059-7029 3 Suppl 1 2018 ESMO open ESMO Open How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. e000357 10.1136/esmoopen-2018-000357 Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little therapeutic progress during the past several (...) decades and still the standard of care remains chemotherapy. Experimental discovery of molecular signatures including the 'BRCAness' highlighted the innate heterogeneity of TNBC, generating the diversity of TNBC phenotypes. As it contributes to enhancing genomic instability, it has widened the therapeutic spectrum of TNBC. In particular, unusual sensitivity to DNA damaging agents was denoted in patients with BRCA deficiency, suggesting therapeutic benefit from platinum and poly(ADP-ribose) polymerase

Full Text available with Trip Pro

2018 ESMO open

158. Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. (PubMed)

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. Background: In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density (...) should be reported instead. Objective: To determine whether breast cancer risk and detection are similar for automated and clinical BI-RADS density measures. Design: Case-control. Setting: San Francisco Mammography Registry and Mayo Clinic. Participants: 1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants. Measurements: Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006

2018 Annals of Internal Medicine

159. Abemaciclib (Verzenio©) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)

Abemaciclib (Verzenio©) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) McGahan L Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2018 Authors' conclusions Overall, abemaciclib with endocrine therapy substantially reduces the risk

2018 Health Technology Assessment (HTA) Database.

160. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial 29443653 2018 04 21 1527-7755 36 11 2018 Apr 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. 1073-1079 10.1200/JCO.2017.76.5719 Purpose Isolated (...) locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at 5 years of median follow-up showed significant benefit of CT for estrogen receptor (ER)-negative ILRR, but additional follow-up was required in ER-positive ILRR. Patients and Methods CALOR was an open-label, randomized trial

2018 EvidenceUpdates